A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
about
Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung CancerThe adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapyTargeted therapies in development for non-small cell lung cancerApproaches to modernize the combination drug development paradigmPhase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis.Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthmaA novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.Antibody phage display libraries: contributions to oncology.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Emerging treatment for advanced lung cancer with EGFR mutation.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Advances in phage display technology for drug discovery.Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative OnThe role of molecular pathology in non-small-cell lung carcinoma-now and in the future.Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer.Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesTargeted therapies in non-small cell lung carcinoma: what have we achieved so far?XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerMolecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyNCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Monoclonal antibodies in lung cancer.Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer.Inhibition of insulin-like growth factor receptor: end of a targeted therapy?Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesPhase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer.Trial watch: Monoclonal antibodies in cancer therapy
P2860
Q26740210-C3B527D8-5FEA-49B7-BE92-161EDB53314EQ27000467-4CE4AA43-6B3A-4A24-818C-0C2790D82391Q27022852-35644D4B-490A-4886-9B6B-2A2E5594D4DAQ28072074-8145671A-1A9A-4B0F-A69B-B92AC862F62CQ33275887-F0C19C0D-8020-4191-AC18-A47B6B21AA95Q33436873-199FC0E8-FB72-4781-A8F4-AB56EF890FDAQ33756365-48732950-5B6F-418B-B2D1-40C642F50DAEQ33846405-959B6B84-A2E8-4114-A733-68D9899B36D4Q33938441-BA600568-C30F-40E1-97AC-4014B077B026Q34323991-7D71A908-1117-4341-A488-34BEEE03A6EDQ34336988-61A31D67-C856-4BD0-BD29-7443C581FD6FQ34483953-CD75544D-42B6-4D68-8879-4BA6F4A52FB4Q35609517-B0351BA8-03AB-47AD-A095-43005EACD4EFQ35614190-8E39D22C-345C-4FB8-A4B6-8FFC55A72600Q36029760-52541DEB-373C-4AEB-82C3-2FB0A3AD1E75Q36040599-12ED2FAC-F5E3-4EE8-BB7B-FBCF58F14D62Q36066604-4C73293A-39E0-4539-B21F-F8DB51EF5E5DQ36102124-D0A7DC4A-81FD-45DB-B915-9D25E28806F4Q36422709-A1AF2554-C3AC-4CBA-ABBA-B2BC639A37DEQ36850900-4916ED4E-75AE-418B-A13F-29D2AD09E6E5Q36999705-81575338-49F4-4F81-835B-C8B64B1B105DQ37138970-1E353886-CE12-49AE-9B69-E7626DCBD089Q37347532-D3A5BCB8-0EA3-4461-AABD-77F85CEEDC7DQ37590339-DA982F4B-D8B0-4628-8411-5A6661D56B38Q38067454-0315AA14-0F4D-4D81-87F8-C64DFD43D83BQ38110796-8551FD7F-E26E-4103-B985-0FB8F9E77B97Q38390012-2830A65C-A85A-4CD0-B36A-7D05213D7B4EQ38525856-FDBAE6CC-9587-426A-B248-4E1EB4D984E0Q38641329-3E2A6FB2-8800-41E2-90B4-7781D2C002EEQ45122871-96D0314A-C914-4A69-9698-119D8FCC4143Q47994454-0AB1A316-39BF-4235-A26F-8CE970B66A0AQ51310879-1C896316-AE14-49B1-AD9D-A573C58F249BQ56932681-FAC5558C-D53C-4D53-8E08-8A96747CFFAF
P2860
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A phase I/II study of erlotini ...... ced non-small cell lung cancer
@ast
A phase I/II study of erlotini ...... ced non-small cell lung cancer
@en
type
label
A phase I/II study of erlotini ...... ced non-small cell lung cancer
@ast
A phase I/II study of erlotini ...... ced non-small cell lung cancer
@en
prefLabel
A phase I/II study of erlotini ...... ced non-small cell lung cancer
@ast
A phase I/II study of erlotini ...... ced non-small cell lung cancer
@en
P2093
P2860
P1476
A phase I/II study of erlotini ...... ced non-small cell lung cancer
@en
P2093
Alex Adjei
Andrew Weickhardt
Araba Adjei
D Ross Camidge
DeLee Maxson
Fred R Hirsch
Gerald Fetterly
P2860
P304
P356
10.1097/JTO.0B013E31823C5B11
P577
2012-02-01T00:00:00Z